Stefan Faderl

The University of Texas MD Anderson Cancer CenterUnited States of America

Stefan Faderl, M.D., Professor of Medicine came to M.D. Anderson in 1996. Dr. Faderl graduated from Ludwig Maximilian Medical School in Munich, Germany in 1990 and received his medical/academic degree (magna cum laude) from the same institution in 1994. Dr. Faderl is board certified in Internal Medicine and Medical Oncology. He specializes in acute and chronic leukemias. His main areas of interest include acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), chronic lymphocytic leukemia (CLL) and its variants, as well as chronic myeloid leukemias (CML). Dr. Faderl has authored and co-authored many abstracts, articles in peer-reviewed journals and book chapters. He serves on numerous editorial boards and is a member of several professional societies such as the American Society of Hematology (ASH), the American College of Physicians (ACP), and the American Society of Clinical Oncology.

1books edited

Latest work with IntechOpen by Stefan Faderl

Acute lymphoblastic leukemia (ALL) has turned from a universally fatal to a highly curable disease in little more than four decades. Even though differences in outcome continue to exist between children and adults, intense efforts are under way to overcome this discrepancy and improve the prognosis of adult patients as well. This exemplary progress in ALL therapy has been possible by the combination of an increasingly better understanding of the biology of the disease, availability of a range of effective drugs, and astute designs and relentless executions of many clinical trials. ALL is a complex disease requiring complex therapy. Whereas this book cannot provide a comprehensive review of every one of its many facets, the chapters from many investigators from around the world nevertheless cover a number of relevant topics: aspects of the epidemiology of ALL in Hispanics, ophthalmologic manifestations of ALL, overviews of current therapy and drug-resistance mechanisms, novel biological pathways and targets, new drugs in development, and long-term consequences of CNS prophylaxis and therapy. The publishers and editor therefore hope that the prospective readers will find enough insight and information for their own endeavors.

Go to the book